301 related articles for article (PubMed ID: 33279908)
1. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
3. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Tada T; Kumada T; Hiraoka A; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Sci Rep; 2021 Jul; 11(1):14474. PubMed ID: 34262065
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
[TBL] [Abstract][Full Text] [Related]
5. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
[TBL] [Abstract][Full Text] [Related]
6. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
7. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
8. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
9. Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma.
Kotoh Y; Saeki I; Yamasaki T; Sasaki R; Tanabe N; Oono T; Maeda M; Hidaka I; Ishikawa T; Takami T; Sakaida I
Clin Nutr; 2021 May; 40(5):3585-3591. PubMed ID: 33386180
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.
Hiraoka A; Kumada T; Michitaka K; Toyoda H; Tada T; Ueki H; Kaneto M; Aibiki T; Okudaira T; Kawakami T; Kawamura T; Yamago H; Suga Y; Miyamoto Y; Tomida H; Azemoto N; Mori K; Miyata H; Ninomiya T; Kawasaki H
J Gastroenterol Hepatol; 2016 May; 31(5):1031-6. PubMed ID: 26647219
[TBL] [Abstract][Full Text] [Related]
11. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
[TBL] [Abstract][Full Text] [Related]
12. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
13. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
Su TS; Yang HM; Zhou Y; Huang Y; Liang P; Cheng T; Chen L; Li LQ; Liang SX
Radiat Oncol; 2019 Mar; 14(1):50. PubMed ID: 30917853
[TBL] [Abstract][Full Text] [Related]
14. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
16. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
[TBL] [Abstract][Full Text] [Related]
17. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study.
Lee SK; Song MJ; Kim SH; Park M
PLoS One; 2019; 14(5):e0216173. PubMed ID: 31048923
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Ramucirumab
Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
[TBL] [Abstract][Full Text] [Related]
19. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.
Hiraoka A; Kato M; Marui K; Murakami T; Onishi K; Adachi T; Matsuoka J; Ueki H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Kuroda T; Iwasaki R; Suga Y; Miyata H; Ninomiya T; Hirooka M; Abe M; Matsuura B; Michitaka K; Hiasa Y
Cancer Med; 2021 Jun; 10(11):3584-3592. PubMed ID: 33960691
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]